Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

Date: October 12, 2016
Pages: 199
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W06908F08E3EN
Leaflet:

Download PDF Leaflet

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016
Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape.

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia.

Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Waldenstrom Macroglobulinemia Overview
Therapeutics Development
Pipeline Products for Waldenstrom Macroglobulinemia - Overview
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies
Waldenstrom Macroglobulinemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Waldenstrom Macroglobulinemia - Products under Development by Companies
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc.
arGEN-X BV
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene, Ltd.
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Gilead Sciences, Inc.
Hutchison MediPharma Limited
IGF Oncology, LLC.
Incyte Corporation
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Novartis AG
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Vivolux AB
Waldenstrom Macroglobulinemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dezapelisib + itacitinib adipate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
765IGF-MTX - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
acalabrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARGX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-3111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-4948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dezapelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DI-B4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTRMWXHS-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-50465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JCAR-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-7583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4059 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
spebrutinib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLX-1570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Waldenstrom Macroglobulinemia - Dormant Projects
Waldenstrom Macroglobulinemia - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 199

LIST OF TABLES

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016
Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016 197

LIST OF FIGURES

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: